title: Intravitreal bevacizumab on myopic choroidal neovascularization that was refractory to or had recurred after photodynamic therapy.
abstract: OBJECTIVE
  To examine the effect of intravitreal injections of bevacizumab for myopic choroidal neovascularization (myopic CNV) that was refractory to or recurred after photodynamic therapy (PDT).
  
  
  METHODS
  Sixteen eyes of 16 consecutive patients with myopic CNVs that were refractory to or had recurred after PDT were studied. The patients were divided into two groups; group 1 consisted of six patients whose CNV recurred after being closed by PDT, and group 2 consisted of ten patients whose CNV did not respond to an earlier treatment. All of the eyes were injected intravitreally with 1.25 mg bevacizumab. The best-corrected visual acuity (BCVA) and fluorescein angiograms (FA) were assessed in both groups.
  
  
  RESULTS
  The mean follow-up period was 15.1 +/- 3.6 months. Patients received a mean of 1.8 +/- 0.8 injections. The mean BCVA in the 16 patients at the final visit was significantly improved over that before the injection. Dye leakage had disappeared in 83.3% of group 1, and in all of the eyes of group 2 at the final visit.
  
  
  CONCLUSIONS
  Intravitreal bevacizumab is effective for myopic CNVs that were either refractory to PDT or had recurred after being regressed by PDT.
authors.affiliation: Department of Ophthalmology and Visual Science, Tokyo Medical and Dental University, 1-5-45 Yushima, Bunkyo-ku, Tokyo, 113-8519, Japan.
authors.forename: Kengo
authors.initials: K
authors.lastname: Hayashi
authors.forename: Kyoko
authors.initials: K
authors.lastname: Ohno-Matsui
authors.forename: Noriaki
authors.initials: N
authors.lastname: Shimada
authors.forename: Muka
authors.initials: M
authors.lastname: Moriyama
authors.forename: Wakako
authors.initials: W
authors.lastname: Hara
authors.forename: Takeshi
authors.initials: T
authors.lastname: Yoshida
authors.forename: Takashi
authors.initials: T
authors.lastname: Tokoro
authors.forename: Manabu
authors.initials: M
authors.lastname: Mochizuki
mesh_terms: D000328:Adult; D000368:Aged; D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D020256:Choroidal Neovascularization / Q000188:drug therapy* / Q000209:etiology / Q000503:physiopathology; D005260:Female; D005451:Fluorescein Angiography; D005500:Follow-Up Studies; D006801:Humans; D007267:Injections; D008297:Male; D008875:Middle Aged; D047728:Myopia, Degenerative / Q000150:complications*; D010778:Photochemotherapy; D011446:Prospective Studies; D012008:Recurrence; D016896:Treatment Outcome; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors; D014792:Visual Acuity / Q000502:physiology; D014822:Vitreous Body
chemical_list: D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab